Skip to content

Jazz Pharmaceuticals

US · JAZZ #1123 by market cap Listed 1970
230.26 -6.19 -2.62%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 234.86 -0.67%
After-hours 230.62 +0.16%
Overnight 235.75 -0.30%
261.62205.06230.262026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on JAZZ?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is +11.8% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 8.9% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Neutral
  • Price is above its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → B

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-21 20:27 UTC

Data coverage: 6 of 6 factors. Missing data is not a zero score.

Overall B-
ValuationGrowthProfitMomentumHealthAnalyst
Valuation C-

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 68.1x Better than 6%
Forward P/E 11.7x Better than 69%
Price / Sales 3.1x Better than 40%
P/E vs own 5-yr range 88th pctl Better than 17%
Growth B+

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 5.3% Better than 48%
Net income CAGR (3Y) 20.2% Better than 73%
Free cash flow CAGR (3Y) 14.0% Better than 58%
Profitability C+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 88.2% Better than 96%
Operating margin 12.1% Better than 57%
Net margin -8.3% Better than 17%
Return on equity -8.5% Better than 21%
Return on invested capital -2.1% Better than 25%
Momentum B

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -9.4% Better than 52%
6-month return -4.0% Better than 48%
12-month return (ex latest month) 21.3% Better than 60%
Distance below 52-week high 13.6% Better than 75%
Financial Health C

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 1.9x Better than 52%
Debt to assets 46.5% Better than 19%
Interest coverage -2.2x Better than 20%
Free cash flow / net income 240.6% Better than 82%
Analyst View B+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 33.4% Better than 53%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -4.67%
1M +7.72%
3M -7.41%
6M -3.66%
YTD +35.45%
1Y +31.02%
3Y +90.85%
5Y +79.37%

Key statistics

Price & volume

Prev close
236.45
Open
235.19
Day range
227.95 - 238.59
Avg price
230.97
Volume
984.70K
Turnover
227.43M
Amplitude
4.50%
52-week range
156.95 - 266.38

Valuation

P/E
-39.43
P/E (TTM)
68.12
P/B
3.53
EPS
-5.84
Net profit
-374.86M
Net assets
4.19B

Share structure

Market cap
14.78B
Float cap
14.33B
Shares out
64.19M
Float shares
62.25M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 67% of range
156.95 266.38

13.6% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-6.19M net over the window

Short interest

Shares short
5.80M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Jazz Pharmaceuticals (JAZZ)?

Jazz Pharmaceuticals last traded at 230.26. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Jazz Pharmaceuticals's market cap?

About 14.78B.

What is the P/E ratio of Jazz Pharmaceuticals?

The trailing twelve-month P/E is 68.12, above its own 5-year average of 59.96 — toward the top of its historical range (89.08% percentile). See the Valuation tab for the full history.

Does Jazz Pharmaceuticals pay a dividend?

Jazz Pharmaceuticals does not currently pay a regular dividend.

Is Jazz Pharmaceuticals a buy according to analysts?

The consensus of 16 analysts is a Buy rating, with an average 12-month price target of 306.38, which implies 33.1% upside from the current price. This is not investment advice.

What is Jazz Pharmaceuticals's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Jazz Pharmaceuticals a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 20:02:26 · For reference only, not investment advice and not tailored to your situation.

Jazz Pharmaceuticals discussion 0 comments

Add a comment